Skip to main content
OpenTrials
Completed

NCT Number: NCT07216651

WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults

This research study is studying WeDosify, an interactive web-based Clinical Decision Support tool that assists healthcare professionals in managing adults with excess weight or obesity using a Glucagon-like peptide-1 (GLP-1) drug treatment such as semaglutide.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Obesity & Overweight Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Amarillo Premier Research (an Objective Health Partnership)

Amarillo, Texas, 37067, United States

About this study

Researchers at Amarillo Premier Research, working with Closed Loop Medicine Ltd (CLM), want to improve how excess weight and obesity are managed. There is a need for tools that support more consistent, data-informed and personalized treatment decisions in weight management. This research focuses on subjects who have recently been prescribed semaglutide (Wegovy). Semaglutide is a widely used medicine that helps patients to lose excess weight and belongs to a group of medicines called Glucagon-like peptide 1s (GLP-1s).

Only subjects who are receiving semaglutide treatment as part of their routine weight management will be invited by the study doctor to join this research study. Once consented, the study doctor will have access to a product called WeDosify, an interactive web-based Clinical Decision Support tool that assists healthcare professionals in managing adults with excess weight or obesity using GLP-1 treatment.

Participation in this study will last approximately 3 months and will include approximately 4 consultations, either study visits to the research center or remote consultations

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants must be 18 years or older.
  • Participants must have a diagnosis of either obesity or overweight.
  • Participants must have initiated first-time semaglutide treatment within the past 4-12 weeks for the management of overweight or obesity, in line with United States Prescribing Information (USPI) and the clinical judgment of the responsible Healthcare Professional (HCP).
  • Participants must have access to and be able to use suitable weighing scales to record their weight before or during consultations.
  • Participants must provide written informed consent to participate in this study, including agreeing to adhere to the associated procedures.

Exclusion criteria

  • Participants with conditions that the Healthcare Professional (HCP) deems would prevent effective use of weighing scales and accurate self-monitoring or reporting of body weight.
  • Failure to satisfy the responsible Healthcare Professional (HCP) of fitness to participate for any other reason.

Treatment and study plan

Primary outcomes

  1. Percentage of participants who persisted on semaglutide treatment over the study period

    Time frame: 3 months

    The primary outcome is treatment persistence during the 3-month observation period, defined as the proportion of participants who remain on semaglutide treatment without discontinuation. Discontinuation will be defined as either a formal cessation of medication or the absence of a prescription renewal within the expected timeframe

Secondary outcomes

  1. Number and percentage of participants discontinuing semaglutide due to unwanted side effects or other clinically significant reasons

    Time frame: 3 months

    Number and percentage of participants discontinuing semaglutide due to unwanted side effects or other clinically significant reasons measured as number and proportion of participants stopping semaglutide and the documented reason for discontinuation

  2. Weight loss from baseline to end of study

    Time frame: 3 months

    Weight loss from baseline to end of study comprising weight loss magnitude and rate, assessed by absolute and percentage change in body weight

  3. Patients' experience of WeDosify and perceived impact of treatment using custom Patient-Reported Experience Measure (PREM) and Patient-Reported Outcome Measure (PROM) questionnaires at end of study

    Time frame: 3 months

    At the end of the study, participants will complete a brief e-questionnaire to capture their experience of the WeDosify-supported treatment journey.

    The questionnaire will use 5-point Likert scale and free text questions to assess:

    • Patient-Reported Outcome Measures (PROMs): to assess the perceived impact of WeDosify on weight and overall health.
    • Patient-Reported Experience Measures (PREMs): to capture satisfaction with WeDosify, including engagement with treatment, clarity of the treatment plan, and motivation to complete it.

  4. Healthcare Professional (HCP) user experience and perceived utility assessed by custom questionnaire at end of study (to include utilization and ease of use)

    Time frame: 3 months

    The Healthcare Professional (HCP) will complete a custom e-questionnaire at the end of the study to capture their overall experience of using the WeDosify tool.

    This e-questionnaire will use 5-point Likert scale and free text questions to assess:

    • Usability and ease of use
    • Perceived value of the treatment options
    • HCP insights on clinical use and potential improvements

Sponsors and collaborators

Lead sponsor

Closed Loop Medicine

Industry

Registry information

Official study title

WeDosify Real-World Evidence: Evaluating a Clinical Decision Support and Patient Engagement Tool for Personalized Semaglutide Dosing in Adults With Overweight or Obesity in the United States

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Oct 14, 2025
Registry last updated
Mar 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.